Abstract
Oral immunotherapy (OIT) and sublingual immunotherapy (SLIT) have emerged as possible treatments for those affected by peanut allergy. Trials have demonstrated safety and efficacy,1 but the ability to introduce peanut afterwards and its long-term effects have not been well described.2,3 At our center, upon completion of an immunotherapy protocol, all subjects demonstrating desensitization to greater than or equal to 300 mg of peanut were instructed to introduce dietary peanut and were invited to participate in this study.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Allergy and Clinical Immunology: In Practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
